The role of project management in the organization of business events in the Republic of Croatia

Odabrana tema istražuje ulogu projektnog menadžmenta u organizaciji recentnih poslovnih događanja na području Republike Hrvatske. U današnje vrijeme svaki poslovni pothvat dobiva naziv projekt, a svaki projekt zahtjeva njegovu kvalitetnu pripremu, realizaciju i postprojektne aktivnosti. Projektni menadžment tada ima veliku ulogu u sastavljanju pravilne organizacijske strukture timova, grupa i/ili poduzeća koja će provesti ideju projekta u djelo. Također, sve ubrzaniji ritam promjena na poslovnim tržištima zahtjeva višu razinu kontinuirane stručne edukacije i informiranosti samih sudionika tržišta o najnovijim kretanjima u djelatnostima u kojima posluju. Tada dolazi do zamjetnog trenda povećanja organiziranja poslovnih konferencija i festivala koje skupno nazivamo poslovna događanja. U sklopu ovog rada provedeno je istraživanje kojim se pokušalo utvrditi kolika je i u kojem obujmu uloga projektnog menadžmenta u organizaciji poslovnih događanja u Hrvatskoj. Ovim istraživanjem zaključeno je da su odstupanja teorije od prakse minimalna. Na uzorku od 26 projektnih menadžera i voditelja projekata dobiveni su rezultati koji ukazuju da su glavne uloge projektnih menadžera kontrola troškova projekta te upravljanje rizicima. Također je bitno zaključiti da su mišljenja svih ispitanika slična te da su odskakanja od prosjeka minimalna, pa čak i zanemariva.The selected topic explores the role of project management in organizing recent business events in the Republic of Croatia. Nowadays, every business venture is called a project, and every project requires its quality preparation, realization and post-project activities. Project management then plays a major role in putting together the proper organizational structure of the teams, groups and / or companies that will put the project idea into action. Also, the accelerating pace of changes in business markets requires a higher level of continuing professional education and awareness of market participants themselves about the latest developments in the industries in which they operate. Then there is a noticeable trend of increasing the organization of business conferences and festivals, collectively referred to as business events. As part of this paper, a study was conducted to determine the extent of the role of project management in organizing business events in Croatia. This research concluded that the deviations of theory from practice are minimal. A sample of 26 project managers obtained results indicating that the main roles of project managers are project cost control and risk management. It is also important to conclude that the opinions of all respondents are similar and that the rebounds from the average are minimal and even negligible

A sandbox for prediction and integration of DNA, RNA, and proteins in single cells

The last decade has witnessed a technological arms race to encode the molecular states of cells into DNA libraries, turning DNA sequencers into scalable single-cell microscopes. Single-cell measurement of chromatin accessibility (DNA), gene expression (RNA), and proteins has revealed rich cellular diversity across tissues, organisms, and disease states. However, single-cell data poses a unique set of challenges. A dataset may comprise millions of cells with tens of thousands of sparse features. Identifying biologically relevant signals from the background sources of technical noise requires innovation in predictive and representational learning. Furthermore, unlike in machine vision or natural language processing, biological ground truth is limited. Here we leverage recent advances in multi-modal single-cell technologies which, by simultaneously measuring two layers of cellular processing in each cell, provide ground truth analogous to language translation. We define three key tasks to predict one modality from another and learn integrated representations of cellular state. We also generate a novel dataset of the human bone marrow specifically designed for benchmarking studies. The dataset and tasks are accessible through an open-source framework that facilitates centralized evaluation of community-submitted methods

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

International audienc

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk